|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
April 12, 2006
"Survey: MS patients want freedom to pick risky drug" [Tysabri]
"Survey has found that more than half would definitely or probably use a drug that significantly reduces frequency of relapse or progression in disability even if the drug involves a 1-in-1,000 chance of a fatal side effect. The survey was conducted by John E. Calfee for the AEI-Brookings Joint Center for Regulatory Studies, established by the American Enterprise Institute and the Brookings Institution." |